Illumina, Inc. $ILMN Shares Bought by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Illumina, Inc. by 5.5%, holding approximately 721,047 shares valued at $57.21 million as of the latest SEC filing.
• Multiple institutional investors made adjustments to their positions in Illumina during the fourth quarter, with notable changes including Jump Financial LLC significantly increasing its stake by 260%.
• Illumina's recent earnings report showed EPS of $1.19, beating estimates, but with revenues of $1.06 billion coming in below expectations at a 4.8% decline year-over-year.

Charles Schwab Investment Management Inc. boosted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 721,047 shares of the life sciences company's stock after purchasing an additional 37,502 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.46% of Illumina worth $57,208,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ILMN. Rakuten Securities Inc. boosted its holdings in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares in the last quarter. Center for Financial Planning Inc. purchased a new stake in Illumina in the first quarter valued at approximately $33,000. Fourth Dimension Wealth LLC purchased a new stake in Illumina in the fourth quarter valued at approximately $40,000. PFS Partners LLC lifted its stake in Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after buying an additional 400 shares during the last quarter. Finally, Golden State Wealth Management LLC lifted its stake in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after buying an additional 292 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Canaccord Genuity Group boosted their price objective on Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research note on Friday, August 1st. Robert W. Baird boosted their price objective on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research note on Monday, July 28th. Guggenheim reduced their price objective on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Piper Sandler reduced their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Finally, Daiwa Capital Markets cut Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective for the company. in a research note on Tuesday, August 12th. Seven investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $124.58.

Illumina Price Performance

NASDAQ:ILMN traded up $0.55 during trading hours on Tuesday, hitting $101.08. The company's stock had a trading volume of 495,439 shares, compared to its average volume of 2,348,943. The business's 50-day moving average is $97.12 and its two-hundred day moving average is $89.34. The company has a market capitalization of $15.54 billion, a PE ratio of 12.80, a PEG ratio of 2.25 and a beta of 1.37. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.Illumina's revenue was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.